Bellerophon Ther­a­peu­tics lets al­most all em­ploy­ees go, looks for deals in wake of PhI­II flop

Less than a month af­ter ad­mit­ting fail­ure in a high­ly an­tic­i­pat­ed tri­al of its on­ly pro­gram, Bellerophon Ther­a­peu­tics is wav­ing the white flag.

The biotech’s board ap­proved lay­ing off “sub­stan­tial­ly all” of its em­ploy­ees, in­clud­ing its ex­ec­u­tive of­fi­cers, Bellerophon dis­closed in a Thurs­day fil­ing. CEO Pe­ter Fer­nan­des, VP of busi­ness op­er­a­tions Parag Shah and VP of en­gi­neer­ing and man­u­fac­tur­ing Mar­tin Dekker will all leave. Bellerophon had 18 full-time staffers at the end of 2022, ac­cord­ing to its an­nu­al re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER